<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5055">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02144402</url>
  </required_header>
  <id_info>
    <org_study_id>2013-1069</org_study_id>
    <nct_id>NCT02144402</nct_id>
  </id_info>
  <brief_title>Growth of Healthy Term Infants Fed Formula Containing DHA-B</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Accelovance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>DSM Nutritional Products, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine if the weight gain of healthy term infants fed a
      commercially available term infant formula supplemented with DHASCO® is similar to that of
      infants fed the same formula supplemented with a new product, DHASCO®-B.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>weight gain (gm/day)</measure>
    <time_frame>through day of life 120</time_frame>
    <safety_issue>No</safety_issue>
    <description>gm/day -calculated from the weight measured at enrollment subtracted from the weight measured at DOL 120 visit, divided by the number of days between the actual visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>length (cm)</measure>
    <time_frame>through day of life 120</time_frame>
    <safety_issue>No</safety_issue>
    <description>Length in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>head circumference (cm)</measure>
    <time_frame>through day of life 120</time_frame>
    <safety_issue>No</safety_issue>
    <description>head circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fatty acid levels (wgt %)</measure>
    <time_frame>at day of life 120</time_frame>
    <safety_issue>No</safety_issue>
    <description>red blood cell (RBC) levels of omega-3 and omega-6 fatty acids (wgt %) in a sample subset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formula intake and tolerance</measure>
    <time_frame>Day of life 30 and 120</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessed by analyzing three-day dietary intake and tolerance forms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>through day of life 120</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AEs collected throughout the study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Growth</condition>
  <condition>Tolerance</condition>
  <condition>Infant Development</condition>
  <arm_group>
    <arm_group_label>infant formula with DHASCO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard infant formula with docosahexaenoic acid (DHA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>infant formula with DHASCO-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard infant formula with DHA-B</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>infant formula with DHASCO</intervention_name>
    <arm_group_label>infant formula with DHASCO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>infant formula with DHASCO-B</intervention_name>
    <arm_group_label>infant formula with DHASCO-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  full term infant (gestational age 37-42 weeks)

          -  birth weight &gt; or equal to 2500 g

          -  singleton infant &lt; or equal to 14 days of age in good health

          -  parent must be &gt;21 years of age

          -  parental consent

        Exclusion Criteria:

          -  congenital malformation or genetic disorder

          -  metabolic anomalies

          -  maternal infectious diseases, alcoholism, substance abuse

          -  mothers with gestational diabetes

          -  participation  in another clinical study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aaron Sanford</last_name>
    <phone>919‐578‐9200</phone>
    <email>asanford@accelovance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Claude Ashley, MD</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Baxley</last_name>
      <phone>334-836-0670</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>JBRKIDS</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>K Henderson</last_name>
      <phone>870-934-3133</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norwich Pediatric</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Vars</last_name>
      <phone>860-889-3835</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Score Physician Alliance</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Hirschfield</last_name>
      <phone>727-381-4305</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Clinical Research</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L Coriaty</last_name>
      <phone>561-791-1233</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pedia Research</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M McCoy</last_name>
      <phone>812-457-4296</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartland Research</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H Schmidt</last_name>
      <phone>316-462-0426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MCHRI</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Hoover</last_name>
      <phone>402-327-6065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B Spaeth</last_name>
      <phone>937-424-9294</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richard Schwartz, MD</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Thorne</last_name>
      <phone>703-938-5555</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
